CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
August 07, 2024 02:00 ET
|
Cellectis Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Provides Financial Results for the Second Quarter 2024
August 06, 2024 16:30 ET
|
Cellectis Inc.
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273...
Monthly information on share capital and company voting rights
August 05, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 26, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
July 25, 2024 16:30 ET
|
Cellectis Inc.
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated1There is an urgent need to develop new therapies for...
CD19/CD20 Bi-Specific CAR-T Pipeline Research Report 2024: In-depth Analysis of the Pipeline Assets, Therapeutic Assessment and Comparative Analysis
July 18, 2024 07:21 ET
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.CD19/CD20 Bi-Specific CAR-T...
Monthly information on share capital and company voting rights
July 05, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
June 28, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...